(Reuters) – The European medicines regulator said on Friday a COVID-19 antibody treatment developed by GSK and Vir Biotechnology can be used to treat patients who are at risk of severe disease and do not need supplemental oxygen.
The rolling review of the drug in ongoing, the European Medicines Agency said.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Sriraj Kalluvila)
